Sino BiologicalInc.
Sino Biological,Inc. provides recombinant protein and antibody reagents for life science researchers in China and internationally. The company offers recombinant proteins, antibodies, cDNA clones, kits, serum-free media, protein modification, qPCR primers, cell lysates, and purification reagents. It also provides comprehensive solutions, including autoimmune disease research, kinase drug discover… Read more
Sino BiologicalInc. - Asset Resilience Ratio
Sino BiologicalInc. (301047) has an Asset Resilience Ratio of 55.52% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Sino BiologicalInc.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Sino BiologicalInc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥3.30 Billion | 55.52% |
| Total Liquid Assets | CN¥3.30 Billion | 55.52% |
Asset Resilience Insights
- Very High Liquidity: Sino BiologicalInc. maintains exceptional liquid asset reserves at 55.52% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Sino BiologicalInc. Industry Peers by Asset Resilience Ratio
Compare Sino BiologicalInc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Sino BiologicalInc. (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Sino BiologicalInc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 61.38% | CN¥3.72 Billion | CN¥6.05 Billion | +7.85pp |
| 2023-12-31 | 53.52% | CN¥3.53 Billion | CN¥6.60 Billion | +1.51pp |
| 2022-12-31 | 52.01% | CN¥3.42 Billion | CN¥6.58 Billion | -0.79pp |
| 2021-12-31 | 52.80% | CN¥3.64 Billion | CN¥6.89 Billion | -19.27pp |
| 2020-12-31 | 72.08% | CN¥1.07 Billion | CN¥1.49 Billion | +49.74pp |
| 2019-12-31 | 22.34% | CN¥41.81 Million | CN¥187.15 Million | -- |